Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7610282 | 0.98 | KDM4E (0.39) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL7610185 | 0.98 | KDM4E (0.41) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| Bromide SCHEMBL7611201 | 0.96 | KDM4E (0.40) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL7612933 | 0.89 | KDM4E (0.47) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL7613702 | 0.87 | KDM4E (0.48) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL7615499 | 0.85 | HIF1A (0.52) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| Bromide SCHEMBL7613738 | 0.85 | KDM4E (0.47) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| Bromide SCHEMBL7619298 | 0.84 | HIF1A (0.50) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL11409292 | 0.71 | GRIN2D (0.30) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21197516 | 0.70 | MAPK1 (0.50) | KDM4EMAPK1HIF1AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152125-A1 | Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases | BRANDEIS UNIVERSITY (US) | 2010-06-17 | — | — | US | claimed |
| EP-2139460-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES | Brandeis University (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008116092-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES | BRANDEIS UNIVERSITY (US) | 2008-09-25 | — | — | WO | claimed |
| EP-0888293-B1 | N-ACYLAMINOALKYLHYDRAZINECARBOXIMIDAMIDES | ALTEON INC (US) | 2002-03-27 | — | — | EP | claimed |
| US-5877217-A | INHIBITING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS OF TARGET PROTEINS. INHIBITING THE DISCOLORATION OF TEETH. | ALTEON INC. (US) | 1999-03-02 | — | — | US | claimed |
| EP-0888293-A1 | N-ACYLAMINOALKYLHYDRAZINECARBOXIMIDAMIDES | ALTEON, INC. (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997023447-A1 | N-ACYLAMINOALKYLHYDRAZINECARBOXIMIDAMIDES | ALTEON INC. (US) | 1997-07-03 | — | — | WO | claimed |
| EP-3085367-A2 | COMPOSITIONS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED | Brandeis University (US) | 2016-10-26 | — | — | EP | disclosed |
| US-8609649-B2 | Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases | BRANDEIS UNIVERSITY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20100152125-A1 | Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases | BRANDEIS UNIVERSITY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2139460-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES | Brandeis University (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116092-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES | BRANDEIS UNIVERSITY (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-0888293-B1 | N-ACYLAMINOALKYLHYDRAZINECARBOXIMIDAMIDES | ALTEON INC (US) | 2002-03-27 | — | — | EP | disclosed |
| US-5877217-A | INHIBITING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS OF TARGET PROTEINS. INHIBITING THE DISCOLORATION OF TEETH. | ALTEON INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0888293-A1 | N-ACYLAMINOALKYLHYDRAZINECARBOXIMIDAMIDES | ALTEON, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997023447-A1 | N-ACYLAMINOALKYLHYDRAZINECARBOXIMIDAMIDES | ALTEON INC. (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152125-A1 | Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases | SOD1, SOD3, AGER | ADRA1A 4036/4885KDM4E 2386/4885MAPK1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.